EXAS Stock Cash Flow Statements

Exact Sciences Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Exact Sciences Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-09-30	2013-06-30	2013-03-31	2012-09-30	2012-06-30	2012-03-31	2011-09-30	2011-06-30	2011-03-31	2010-09-30	2010-06-30	2010-03-31	2009-09-30	2009-06-30	2009-03-31	2008-09-30	2008-06-30	2008-03-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30	2006-03-31	2005-12-31	2005-09-30	2005-06-30	2005-03-31	2004-09-30	2004-06-30	2004-03-31	2003-09-30	2003-06-30	2003-03-31	2002-03-31	2001-09-30

cash flows from operating activities:
net income	-1,185,000	-101,215,000	-864,585,000	-38,236,000	-15,808,000	-110,228,000	-49,766,000	794,000	-81,026,000	-74,151,000	-127,745,000	-148,761,000	-166,063,000	-180,937,000	-220,611,000	-166,938,000	-176,912,000	-31,164,000	-436,810,000	-219,884,000	-86,142,000	-105,697,000	77,945,000	-40,459,000	-38,420,000	-83,059,000	-53,974,000	-45,364,000	-36,387,000	-39,424,000	-21,764,000	-26,897,000	-30,790,000	-34,946,000	-37,170,000	-37,803,000	-44,765,000	-47,473,000	-39,991,000	-42,945,000	-39,066,000	-35,801,000	-32,444,000	-32,060,000	-19,437,000	-16,107,000	-11,160,000	-12,314,000	-10,854,000	-12,952,000	-14,836,000	-10,645,000	-7,773,000	-6,625,000	-4,373,000	-3,382,000	-2,477,000	-2,124,000	-1,041,000	-2,394,000	-3,839,000	-3,014,000	-2,100,000	-2,518,000	-4,195,000	-1,825,000	-1,920,000	-2,423,000	-3,083,000	-3,246,000	-4,163,000	11,810,480	-3,289,000	-3,951,000	-4,585,000	-4,403,000	-4,279,000	-5,291,000	-6,862,000	-7,884,000	-7,883,000	-7,585,885	-5,729,378
adjustments to reconcile net income to net cash from operating activities:
depreciation	31,097,000	29,960,000	29,046,000	30,336,000	29,687,000	30,632,000	30,861,000	29,262,000	27,510,000	26,815,000	26,567,000	25,043,000																																																									89,000	101,000	198,000	-597,250	162,000	226,000	210,000	276,000	299,000	336,000	619,000	434,000	469,000
loss on non-marketable and marketable equity securities	-2,136,000	2,900,000
deferred tax expense	-6,000	-1,007,000		-398,000	428,000	1,797,000			-589,000	1,261,000
stock-based compensation	55,783,000	54,618,000	49,203,000	48,757,000	56,555,000	60,370,000	58,577,000	61,871,000	61,725,000	49,139,000	45,917,000	49,533,000	58,932,000	52,441,000	55,883,000	63,603,000	56,285,000	77,292,000	41,831,000	41,476,000	40,039,000	29,560,000	47,826,000	24,348,000	20,143,000	16,166,000	15,710,000	16,498,000	15,593,000	12,463,000	12,510,000	10,778,000	6,095,000	6,129,000	6,959,000	6,166,000	4,507,000	6,100,000	4,902,000	4,980,000	4,548,000	3,620,000	2,877,000	4,165,000	2,483,000	1,995,000	1,849,000	2,856,000	955,000	1,565,000	1,424,000	1,035,000	1,101,000	1,068,000	686,000	640,000	508,000	527,000	624,000	711,000	623,000	265,000	229,000	301,000	1,376,000	720,000	409,000	561,000	668,000	710,000	1,067,000	-273,495	-81,000								328,000
gain on settlements of convertible notes				0				0	0	-10,324,000
amortization of acquired intangible assets	24,186,000	24,101,000	24,101,000	24,435,000	23,311,000	23,311,000	23,311,000	22,992,000	22,929,000	22,928,000	22,914,000	23,526,000	26,356,000	24,654,000	24,047,000	23,940,000	23,824,000	23,190,000		23,430,000	23,430,000	23,339,000
impairment of long-lived and indefinite-lived assets	0	6,251,000
gain on contingent consideration from sale of asset							-4,400,000
remeasurement of contingent consideration liabilities	4,909,000	8,287,000	-1,020,000	5,310,000	-13,239,000	5,603,000	-4,993,000
non-cash lease expense	6,730,000	6,753,000	6,281,000	6,603,000	6,990,000	7,052,000	6,973,000	7,141,000	6,971,000	6,806,000	4,187,000	7,171,000	9,918,000	7,363,000	7,478,000	6,510,000	6,097,000	5,740,000	4,679,000	4,181,000	-3,330,000	10,190,000	2,746,000	919,000	917,000	845,000
other	3,993,000	2,001,000	918,000	1,230,000	-2,896,000	229,000	-3,131,000	-435,000
changes in assets and liabilities:
accounts receivable	-73,014,000	-30,072,000	15,151,000	-509,000	-23,365,000	-37,536,000	-3,110,000	-19,814,000	4,942,000	-25,434,000	33,120,000	-2,664,000	19,612,000	11,020,000	39,188,000	-23,033,000	31,945,000	-22,950,000	-26,884,000	-42,998,000	-24,322,000	-6,322,000	8,933,000	-18,297,000	-6,718,000	-11,856,000	-1,795,000	-5,648,000	-1,693,000	-8,156,000	-1,866,000	-1,598,000	-6,377,000	-7,688,000	-663,000	-422,000	-1,820,000	-688,000	-724,000	-2,058,000	-570,000	-205,000
inventory	5,106,000	-14,175,000	-25,395,000	-9,612,000	1,161,000	-1,065,000	5,384,000	-543,000	-6,704,000	-5,827,000	-3,526,000	473,000	-2,214,000	-7,964,000	-8,130,000	-5,358,000	1,035,000	3,232,000	-11,838,000	1,788,000	-12,791,000	-7,469,000	-4,516,000	-5,892,000	-3,512,000	-5,121,000	-139,000	-3,208,000	-3,029,000	-6,353,000	-7,963,000	-5,654,000	-4,551,000	-1,026,000	833,000	738,000	-247,000	-1,480,000	-645,000	243,000	-852,000	-1,406,000
operating lease liabilities	-7,266,000	-6,575,000	-6,438,000	-6,388,000	-6,354,000	-6,603,000	-6,960,000	-6,975,000	-6,784,000	-5,982,000	-4,404,000	-5,574,000	-5,491,000	-5,177,000	-4,851,000	-4,739,000	-3,975,000	-3,120,000	-2,649,000	-1,138,000	-2,787,000	-2,210,000
accounts payable and accrued liabilities	39,415,000	58,633,000	5,280,000	56,123,000	35,650,000	-53,515,000	31,666,000	2,330,000	53,571,000	-4,817,000	37,088,000	-9,929,000	-13,291,000	-66,048,000	105,456,000	37,206,000	43,000,000	-15,862,000	62,773,000	39,979,000	-29,291,000	-18,296,000
other assets	8,624,000	-3,837,000	-8,681,000	3,639,000	9,305,000	-6,586,000	-7,932,000	5,938,000	3,998,000	-13,622,000
other liabilities	-7,219,000	-5,814,000	-1,389,000	1,174,000	12,845,000	-2,904,000	7,607,000	-5,508,000	5,395,000	-1,161,000
net cash from operating activities	89,017,000	30,809,000	47,063,000	138,719,000	107,065,000	-82,311,000	69,549,000	24,361,000	100,424,000	-38,215,000	52,037,000	-40,926,000	-60,916,000	-173,754,000	-24,572,000	-40,774,000	40,337,000	-77,227,000	111,404,000	81,775,000	-6,870,000	-49,827,000	-28,684,000	-29,080,000	17,161,000	-74,407,000	-1,236,000	-4,053,000	-25,514,000	-38,522,000	-764,000	-5,450,000	-31,872,000	-33,638,000	-27,129,000	-24,966,000	-35,624,000	-42,347,000	-33,804,000	-34,525,000	-31,187,000	-34,501,000
capex	-42,342,000	-31,174,000	-36,316,000	-26,158,000	-35,866,000	-37,649,000	-34,922,000	-25,187,000	-34,721,000	-29,360,000	-72,876,000	-44,637,000	-63,326,000	-33,623,000	-59,392,000	-38,870,000	-24,584,000	-12,920,000	-16,570,000	-14,327,000	-20,770,000	-12,685,000	-40,832,000	-51,522,000	-68,791,000	-10,657,000	-52,106,000	-53,623,000	-29,036,000	-15,328,000	-24,038,000	-15,794,000	-5,903,000	-2,745,000	-2,685,000	-5,751,000	-4,026,000	-2,389,000	-2,544,000	-6,798,000	-7,535,000	-3,207,000
free cash flows	46,675,000	-365,000	10,747,000	112,561,000	71,199,000	-119,960,000	34,627,000	-826,000	65,703,000	-67,575,000	-20,839,000	-85,563,000	-124,242,000	-207,377,000	-83,964,000	-79,644,000	15,753,000	-90,147,000	94,834,000	67,448,000	-27,640,000	-62,512,000	-69,516,000	-80,602,000	-51,630,000	-85,064,000	-53,342,000	-57,676,000	-54,550,000	-53,850,000	-24,802,000	-21,244,000	-37,775,000	-36,383,000	-29,814,000	-30,717,000	-39,650,000	-44,736,000	-36,348,000	-41,323,000	-38,722,000	-37,708,000
cash flows from investing activities:
purchases of marketable securities	-13,481,000	-80,315,000	-59,646,000	-81,013,000	-147,047,000	-177,325,000	-64,758,000	-24,440,000	-42,067,000	-8,589,000	-29,048,000	-23,328,000	-8,843,000	-70,267,000	-142,493,000	-106,268,000	-752,791,000	-162,498,000	-199,941,000	-249,927,000	-214,917,000	-425,168,000	-29,988,000	-92,542,000	-248,700,000	-262,887,000	-110,844,000	-186,806,000	-266,354,000	-628,502,000	-12,012,000	-156,791,000	-157,685,000	-30,563,000	-38,533,000	-145,338,000	0	-6,118,000	-7,057,000	-178,679,000	-8,173,000	-11,145,000
maturities and sales of marketable securities	252,872,000	77,557,000	54,905,000	70,581,000	36,357,000	43,978,000	35,102,000	57,229,000	149,493,000	121,332,000		108,130,000	118,680,000	150,630,000		99,450,000	89,085,000	236,295,000		291,424,000	229,340,000	39,143,000
purchases of property, plant and equipment	-42,342,000	-31,174,000	-36,316,000	-26,158,000	-35,866,000	-37,649,000	-34,922,000	-25,187,000	-34,721,000	-29,360,000	-72,876,000	-44,637,000	-63,326,000	-33,623,000	-59,392,000	-38,870,000	-24,584,000	-12,920,000	-16,570,000	-14,327,000	-20,770,000	-12,685,000	-40,832,000	-51,522,000	-68,791,000	-10,657,000
purchases of non-marketable investments
proceeds from contingent consideration receivable
other investing activities	650,000	-505,000	0	-20,000	0	-205,000	500,000	250,000			-500,000	0	-42,000	-7,000	-500,000	0	-103,000	-141,000	-137,000	272,000	-186,000	-330,000
net cash from investing activities	224,895,000	-34,437,000	-41,872,000	-81,716,000	-147,129,000	-171,438,000	-66,767,000	-32,969,000	66,474,000	82,941,000	-58,159,000	65,005,000	21,659,000	45,561,000	78,437,000	-49,243,000	-793,767,000	-317,512,000	-306,638,000	16,828,000	-6,380,000	-405,847,000	-834,774,000	857,442,000	-102,672,000	-41,069,000	-9,417,000	-78,988,000	-130,778,000	-562,731,000	24,654,000	-126,596,000	-82,791,000	23,928,000	9,290,000	-105,280,000	31,298,000	53,173,000	40,956,000	-141,975,000	19,500,000	16,764,000				17,304,000			6,824,000													2,221,000	3,192,000	2,560,000	5,499,000	1,591,000	1,516,000	8,000	-3,209,000	6,104,000	1,622,000	-16,806,240	2,773,000	11,919,000	2,130,000				-7,968,000	9,837,000	2,568,000
cash flows from financing activities:
payments on settlement of convertible notes	0	-249,172,000																	0	0	0	-150,054,000	0	0	-1,000	-493,355,000
proceeds from exercise of common stock options, net of cash paid for taxes	293,000	-422,000		2,132,000	43,000	-1,408,000
proceeds in connection with the company’s employee stock purchase plan				0				0				0				0				0																								0
payments on accounts receivable securitization facility			0	0
proceeds from issuance of convertible notes			0	0			0	0	0	137,976,000									0	0	0	1,125,547,000	0	-2,000	-57,000	729,536,000	-1,000	6,000	225,334,000	671,091,000
payments on settlement of contingent consideration liabilities
other financing activities	-1,840,000	-6,577,000	-2,210,000	-2,358,000	-11,592,000	-1,594,000	-2,267,000	-985,000	-1,155,000	-5,344,000	-417,000	-706,000	-2,860,000	-1,547,000	-544,000	-1,674,000	-1,554,000	-1,514,000	-2,067,000	-312,000	-313,000	-313,000
net cash from financing activities	-4,514,000	-256,171,000	10,499,000	-226,000	224,603,000	-3,002,000	10,037,000	92,000	16,041,000	133,596,000	10,103,000	235,000	63,412,000	2,735,000	-12,196,000	81,000	13,342,000	7,245,000	879,859,000	4,158,000	16,124,000	979,480,000	6,624,000	980,000	5,451,000	240,126,000	9,354,000	19,074,000	233,277,000	672,437,000	2,718,000	2,460,000	255,775,000	3,000	3,366,000	144,706,000	1,267,000	247,000	2,509,000	174,166,000	4,795,000	295,000	105,865,000	136,000	138,025,000	2,000	636,000	73,616,000	8,000	57,981,000	222,000	1,642,000	331,000	211,000	14,000	1,434,000	17,743,000	1,109,000	804,000	8,071,000	22,614,000	100,000	0	6,000	117,000	0	15,000	354,000	48,000	18,000	53,000	-137,863	65,000	4,000	69,000	105,000	266,000	43,566,000	847,000	124,000	181,000	251,460	139,980
effects of exchange rate changes on cash and cash equivalents	574,000	290,000	-3,721,000	1,873,000	-306,000	-1,140,000	1,947,000	-1,235,000	59,000	550,000	3,206,000	-2,429,000	-510,000	-237,000										-66,000	-82,000	120,000	24,000	10,000	-18,000	20,000	46,000	16,000			-51,000
net increase in cash, cash equivalents and restricted cash				58,650,000	184,233,000	-257,891,000	14,766,000	-9,751,000	182,998,000	178,872,000					41,692,000	-89,936,000	-740,088,000	-387,494,000	684,625,000	102,761,000	2,874,000	523,806,000
cash, cash equivalents and restricted cash, beginning of period	0	606,636,000		0	0	609,675,000		0	0	242,790,000		0	0	315,768,000		0	0	1,491,594,000		0	0	177,528,000
cash, cash equivalents and restricted cash, end of period	309,972,000	347,127,000		58,650,000	184,233,000	351,784,000		-9,751,000	182,998,000	421,662,000		21,885,000	23,645,000	190,073,000		-89,936,000	-740,088,000	1,104,100,000		102,761,000	2,874,000	701,334,000
loss on contingent consideration from sale of asset						268,000
net decrease in cash, cash equivalents and restricted cash		-259,509,000										21,885,000	23,645,000	-125,695,000
(gain) loss on non-marketable and marketable equity investments
deferred tax benefit							-676,000				-2,555,000	-4,406,000	-3,028,000	-1,912,000	-4,453,000	-4,207,000	-1,379,000	-243,130,000	-1,886,000	-4,754,000	-1,304,000	-1,918,000	-184,768,000	643,000	-464,000	-520,000					116,000
gain on settlement of convertible notes
loss on sale of asset											0
changes in assets and liabilities, net of effects of acquisition:
proceeds from sale of asset											0
maturities and sales of investments in non-marketable securities
investments in non-marketable securities
business combination, net of cash acquired and issuance costs											-15,371,000	0
asset acquisitions, net of cash acquired
proceeds from accounts receivable securitization facility											0	0
proceeds from exercise of common stock options							304,000	1,077,000	852,000	964,000	558,000	941,000	743,000	4,282,000	1,065,000	1,755,000	2,858,000	8,759,000	11,669,000	4,470,000	6,638,000	4,300,000	2,398,000	1,391,000	1,348,000	3,650,000	260,000	731,000	4,254,000	1,391,000	1,753,000	2,578,000	725,000	47,000	2,362,000	500,000	261,000	288,000	287,000	102,000	473,000	386,000	2,216,000	231,000	105,000	88,000
proceeds in connection with the company's employee stock purchase plan																							4,259,000	0			2,232,000	2,000			1,212,000	0			1,051,000	1,000			960,000	1,000
net increase in cash, cash equivalents, and restricted cash
cash, cash equivalents, and restricted cash at the beginning of period
cash, cash equivalents, and restricted cash at the end of period
impairment of long-lived assets				18,698,000	8,152,000	4,446,000	0	0	552,000	69,000	3,432,000
remeasurement of contingent consideration from sale of asset				-3,100,000
business combination, net of cash acquired															-84,181,000	0	-72,301,000	-343,248,000	0	-4,000	153,000	-6,807,000
asset acquisition, net of cash acquired
purchases of non-marketable securities
sales of investments in non-marketable securities
loss on non-marketable and marketable equity investments					-1,303,000	2,418,000
investments in privately held companies						-237,000	-10,274,000	-117,000	-5,731,000	-442,000		-160,000	-25,495,000	-1,172,000		-3,555,000	0	-10,000,000
post-combination expense for acceleration of unvested equity															0	0	0	80,960,000
asset acquisition ipr&d expense															0	0	33,074,000	52,263,000
maturities and sales of investments in privately held companies
payments on construction loan
cash, cash equivalents and restricted cash at the beginning of period
cash, cash equivalents and restricted cash at the end of period
unrealized loss on equity investments								5,523,000	7,090,000	3,009,000
realized (gain) loss on non-marketable investment
sales of investments in privately held companies
realized gain on non-marketable investment
remeasurement of contingent consideration									4,250,000	-8,937,000	1,002,000	-5,860,000	-25,079,000	-26,680,000	-4,626,000	1,785,000	6,322,000	2,879,000
loss on disposal of property, plant and equipment										284,000	-220,000	1,917,000	-155,000	321,000	127,000	289,000	302,000	337,000	1,540,000	280,000	378,000	272,000	514,000	669,000	129,000	82,000
amortization of deferred financing costs, convertible note debt discount and issuance costs, and other liabilities										1,783,000	1,854,000	1,853,000	1,720,000	1,700,000	1,735,000	1,666,000	1,649,000	1,633,000
accretion (amortization) of discount (premium) on short-term investments										-54,000
unrealized (gain) loss on equity investments													2,897,000	1,350,000	-445,000
realized (gain) loss on non-marketable investments
loss on settlement of convertible notes																			0	0	0	7,954,000	0	0	0	10,558,000
amortization of premium on short-term investments											50,000	302,000	537,000	956,000		1,649,000	1,177,000	439,000		537,000	450,000	53,000	-213,000	-309,000	-1,274,000	-1,306,000	-1,320,000	-1,189,000	-877,000	-515,000	9,000	-1,000	20,000	37,000	51,000	66,000	132,000	214,000	303,000	318,000	325,000	377,000	214,000	258,000	225,000	145,000	188,000	130,000	140,000
other assets and liabilities											6,079,000	-1,990,000	2,337,000	-7,834,000	-37,801,000	-20,040,000	-1,127,000	1,033,000	6,767,000	-8,460,000	52,857,000	-9,438,000
maturities of marketable securities																									215,059,000	232,615,000	171,884,000	161,445,000	164,681,000	81,161,000	75,981,000	49,010,000	89,239,000	57,236,000	50,508,000	45,809,000	35,324,000	61,680,000	52,457,000	43,502,000	35,208,000	31,116,000	26,483,000	32,921,000	20,349,000	24,419,000	15,421,000	13,636,000	16,431,000	15,251,000	10,238,000	16,334,000	4,752,000	11,128,000	1,498,000	1,672,000	3,670,000	1,756,000	11,974,000			2,243,000	4,213,000	5,080,000	7,868,000	7,226,000	8,850,000	7,871,000	9,671,000	11,397,000	7,361,000	-32,116,578	9,137,000	14,509,000	8,511,000
investment in privately held companies
proceeds from sale of common stock, net of issuance costs																															-1,000	-74,000			-5,000				0				100,916,000	-6,000			-6,000									0			0
realized (gain) loss on preferred stock investment
asset acquisition																0	-33,073,000	-25,000,000
realized gain on preferred stock investment															0	0	0	-30,500,000
intangible asset impairment charge															0				0
depreciation and amortization														22,993,000	21,078,000	22,260,000	21,499,000	20,508,000		19,713,000	17,626,000	16,006,000																																					18,000																							449,494	325,252
unrealized gain on equity investments																	-2,479,000	-7,000
depreciation and other amortization
unrealized net (gain) loss on revaluation of equity securities
loss on preferred stock investment
amortization of convertible note debt discount and issuance costs																			21,257,000	20,584,000	20,085,000	14,553,000
amortization of deferred financing costs and other liabilities																			-275,000	-1,109,000	-1,432,000	-1,073,000
amortization of acquired intangibles
proceeds from construction loan, net deferred financing costs
unrealized loss on revaluation of marketable equity securities																					-336,000	669,000
proceeds from construction loan																								0	24,000	295,000	6,989,000	16,174,000
realized gain on sale of marketable securities																							-15,000
unrealized net income on revaluation of equity securities
amortization of liabilities																							-32,123,000	9,173,000	10,063,000	8,420,000
purchases of intangible assets
proceeds from financing obligation, net payments on mortgage payable
depreciation and amortization of property, plant and equipment																								8,351,000	7,075,000	6,324,000
amortization of intangible assets																								811,000	805,000	810,000	755,000	619,000	616,000	612,000	410,000	355,000	240,000	50,000	50,000	50,000	50,000	50,000
accrued interest																								-1,702,000	1,804,000	-3,106,000	2,692,000	-2,253,000	2,747,000	1,407,000									0	0	-112,000	6,000	6,000	5,000	5,000	6,000	6,000	5,000	5,000	5,000	5,000	5,000	5,000	5,000	5,000	5,000	5,000	5,000
prepaid expenses and other current assets																								4,716,000	-730,000	-3,552,000	4,701,000	-7,367,000	-3,598,000	-2,812,000	396,000	-1,633,000	571,000	-329,000	-941,000	1,622,000	427,000	-347,000	-1,150,000	-1,616,000	73,000	-364,000																							75,000			131,000	378,000			-618,318
accounts payable																								-738,000	2,344,000	-10,589,000	-5,271,000	21,746,000	-1,282,000	-3,861,000	7,361,000	6,495,000	1,346,000	181,000	-1,625,000	-800,000	294,000	-467,000	1,805,000	158,000	-656,000	-646,000	-1,988,000			570,000				263,000	-182,000	184,000				-182,000	272,000	134,000					75,000	30,000	103,000													129,000			229,000	354,772
accrued liabilities																								-8,708,000	25,596,000	7,891,000	23,344,000	8,198,000	-9,175,000	-623,000	5,848,000	9,574,000	-1,472,000	1,204,000	1,896,000	2,802,000	3,315,000	-664,000	-381,000	4,624,000	4,654,000	-1,473,000
other short-term liabilities																								112,000	144,000	-60,000	85,000	18,000	98,000	-29,000	148,000
other long-term liabilities																								-678,000	19,072,000	-2,092,000
other long-term assets																								1,301,000	-1,321,000	-22,734,000
internally developed software																								-150,000	-240,000	-140,000	-443,000	-4,000	-69,000	-62,000	-45,000
proceeds from financing obligation																											12,000
payments of deferred financing costs																											1,000	-1,000
payments on mortgage payable																											0	-4,588,000	-45,000	-45,000	-44,000	-44,000	-42,000	-44,000	-42,000	-42,000	-41,000	-41,000
stock issuance costs

net increase in cash and cash equivalents																								829,276,000	-80,142,000	124,770,000	-1,275,000	-63,957,000	76,967,000	71,204,000	26,654,000	-129,570,000	141,201,000	-9,715,000	-14,524,000	14,435,000	-3,141,000	11,016,000	9,613,000	-2,243,000	-6,914,000	-17,452,000	30,302,000	7,121,000	2,902,000	4,955,000													10,490,000			565,000											-501,000					9,979,000					-4,596,378
cash and cash equivalents, beginning of period																								0	0	160,430,000	0	0	0	77,491,000	0	0	0	48,921,000	0	0	0	41,135,000	0	0	0	58,131,000	0	0	0	12,851,000	0	0	13,345,000	0	0	35,781,000	0	0	78,752,000	0	0	21,924,000	0	0	4,937,000	0	0	4,486,000	0	0	4,831,000		0	0	13,007,000	-13,078,908	0	0	13,092,000	0	0	14,200,000	0	0	17,439,000	56,842,722	0
cash and cash equivalents, end of period																								829,276,000	-80,142,000	285,200,000	-1,275,000	-63,957,000	76,967,000	148,695,000	26,654,000	-129,570,000	141,201,000	39,206,000	-14,524,000	14,435,000	-3,141,000	52,151,000	9,613,000	-2,243,000	-6,914,000	40,679,000	30,302,000	7,121,000	2,902,000	17,806,000	-11,808,000	13,465,000	8,053,000	6,634,000	-6,266,000	12,292,000	-33,269,000	-33,809,000	72,073,000	-3,417,000	6,061,000	18,171,000	10,490,000	8,693,000	3,595,000	565,000	1,505,000	3,999,000	3,329,000	-17,000	3,852,000		-5,841,000	3,441,000	10,391,000	-17,110,993	-501,000	8,292,000	9,333,000	2,708,000	-10,334,000	24,179,000	1,369,000	2,953,000	11,783,000	50,195,303	-4,596,378
supplemental disclosure of non-cash investing and financing activities:
property, plant and equipment acquired but not paid																								-7,469,000	-17,717,000	42,119,000
unrealized gain on available-for-sale investments, before tax																								-2,697,000	1,952,000	2,176,000
issuance of 86,532 and 86,882 shares of common stock to fund the company’s 401(k) matching contribution for 2018 and 2017, respectively																								0
issuance of 2,159,017 shares of common stock upon settlement of convertible notes
retirement of equity component of convertible notes settled																								0	0	-300,768,000
interest paid																								3,729,000	174,000	5,214,000	0	4,541,000	49,000	48,000	50,000	50,000	51,000	50,000	52,000	52,000	52,000	53,000
issuance of 2,158,991 shares of common stock upon settlement of convertible notes																									0	182,435,000
long-term obligations																										18,492,000
issuance of 86,532 and 86,828 shares of common stock to fund the company’s 401(k) matching contribution for 2018 and 2017, respectively																										7,409,000
depreciation and amortization of property and equipment																											6,133,000	5,541,000
loss on disposal of property and equipment																											-500,000	757,000	-2,000	98,000	653,000	210,000	71,000	20,000	50,000	57,000											0	66,000	25,000
amortization of debt discount																											7,732,000	7,737,000	6,171,000	4,651,000
amortization of debt issuance costs																											676,000	677,000	518,000	402,000
amortization of other liabilities																											-691,000	-673,000	-603,000	-533,000	-475,000	-430,000	-392,000	-377,000	-300,000	-268,000	-237,000	-208,000	-174,000	-158,000
amortization of deferred financing costs																											20,000	37,000	26,000	23,000	14,000	14,000	12,000	14,000	12,000	14,000	13,000	13,000	11,000
proceeds from refundable tax credits
lease incentive obligation																											-159,000	-179,000	836,000	-153,000	-154,000	-154,000	-154,000	-154,000	-153,000	-136,000	-153,000	130,000	-138,000	-139,000	-138,000	-138,000
purchases of property and equipment																											-52,106,000	-53,623,000	-29,036,000	-15,328,000	-24,038,000	-15,794,000	-5,903,000	-2,745,000	-2,685,000	-5,751,000	-4,026,000	-2,389,000	-2,544,000	-6,798,000	-7,535,000	-3,207,000
business acquisition, net of cash acquired																															16,000
investment in privately-held company
payments on capital lease
property and equipment acquired but not paid																											7,738,000	693,000	12,508,000	12,513,000	4,888,000	1,825,000	1,330,000	775,000	106,000	-506,000	21,000	1,034,000
property acquired under build-to-suit lease
unrealized loss on available-for-sale investments																																																				-35,000
issuance of 86,882, 158,717, and 341,507 shares of common stock to fund the company’s 401(k) matching contribution for 2017, 2016, and 2015, respectively
business acquisition contingent consideration liability
unrealized gain on available-for-sale investments																														-1,606,000	-482,000	49,000			-180,000	-145,000	82,000	473,000	-540,000	75,000	-59,000	195,000	-109,000			8,000	33,000	14,000	-7,000	39,000				-11,000	-2,000	-18,000	-1,000	-1,000
issuance of 86,882 and 158,717 shares of common stock to fund the company’s 401(k) matching contribution for 2017 and 2016, respectively																												0
depreciation and amortization of fixed assets																														4,281,000	3,993,000	3,751,000	3,509,000	3,247,000	3,072,000	2,948,000	2,816,000	2,473,000	2,188,000	2,035,000	1,790,000	1,587,000
issuance of 86,828 and 158,717 shares of common stock to fund the company’s 401(k) matching contribution for 2017 and 2016, respectively																														4,300,000
forgiveness of long-term debt																																							0	0
purchased intangible assets																															-12,248,000
payments on capital lease obligations																																							0	-177,000	-92,000	-91,000
proceeds from mortgage payable																																							1,306,000	100,000
issuance of 158,717, 341,507 and 21,826 shares of common stock to fund the company’s 401(k) matching contribution for 2016, 2015, and 2014 respectively
issuance of 158,717 and 341,507 shares of common stock to fund the company’s 401(k) matching contribution for 2016 and 2015, respectively																																0	0	3,008,000
amortization of deferred license fees
proceeds from new market tax credit financing agreements
issuance of 341,507, 21,826 and 32,666 shares of common stock to fund the company’s 401(k) matching contribution for 2015, 2014 and 2013, respectively
issuance of 341,507 and 21,826 shares of common stock to fund the company’s 401(k) matching contribution for 2015 and 2014, respectively
effects of exchange rate on cash and cash equivalents																																					-82,000	-57,000	-48,000	91,000	-22,000	-10,000
issuance of 340,950 and 21,826 shares of common stock to fund the company’s 401(k) matching contribution for 2015 and 2014, respectively																																					5,000	2,146,000
issuance of 21,826, 32,666 and 30,538 shares of common stock to fund the company’s 401(k) matching contribution for 2014, 2013 and 2012, respectively
issuance of 21,826 and 32,669 shares of common stock to fund the company’s 401(k) matching contribution for 2014 and 2013, respectively																																								0
amortization of other long-term liabilities																																										-58,000
issuance of 21,826 and 32,666 shares of common stock to fund the company’s 401(k) matching contribution for 2014 and 2013, respectively																																										835,000
warrant licensing expense																																																		0	125,000	27,000			27,000	26,000	27,000	27,000
restricted stock licensing expense																																																		0
accrued expenses																																											2,832,000	2,568,000	1,754,000	1,456,000	1,498,000	1,143,000	372,000	355,000			429,000			207,000									516,000	258,000	38,000	289,000	-64,000							67,000	60,000	344,000				233,528	814,623
issuance of 32,666, 30,538, and 32,872 shares of common stock to fund the company’s 401(k) matching contribution for 2013, 2012, and 2011, respectively
laboratory equipment acquired with a capital lease
depreciation of property and equipment																																															330,000	332,000	314,000	249,000	215,000	202,000	117,000	78,000	67,000	62,000
issuance of 32,269 and 30,534 shares of common stock to fund the company’s 401(k) matching contribution for 2013 and 2012, respectively
depreciation of fixed assets																																													688,000	656,000												48,000			12,000			59,000
loss on disposal of fixed asset
issuance of 32,266 and 30,534 shares of common stock to fund the company’s 401(k) matching contribution for 2013 and 2012, respectively
issuance of 32,666 and 30,534 shares of common stock to fund the company’s 401(k) matching contribution for 2013 and 2012, respectively																																														456,000
proceeds from exercise of common stock options and stock purchase plan																																															726,000	396,000	90,000	226,000	222,000	1,642,000	331,000	211,000	14,000	0	146,000	147,000	704,000	9,000	14,000	0	0	6,000	17,000	0	15,000	134,000	48,000	18,000	53,000	-137,863	65,000	5,000	68,000	102,000	2,000	160,000	845,000	123,000	127,000
issuance of 30,534 and 32,872 shares of common stock to fund the company’s 401(k) matching contribution for 2012 and 2011, respectively																																															0
conversion of accrued expenses into 34,442 and 34,336 shares of common stock in connection with the company’s employee stock purchase plan for 2013 and 2012, respectively.																																															0
net decrease in cash and cash equivalents
issuance of 30,534 and 32,872 shares of common stock to fund the
company’s 401(k) matching contribution for 2012 and 2011, respectively																																																	354,000
issuance of 32,872 and 27,872 shares of common stock to fund the company’s 401(k) matching contribution for 2011 and 2010, respectively																																																		0	0	274,000
conversion of accrued expenses into 34,336 and 27,110 shares of common stock in connection with the company’s employee stock purchase plan for 2012 and 2011, respectively																																																		0
proceeds from genzyme collaboration, license and purchase agreement																																																								934,000	0	962,000	0	0	16,650,000
decrease in restricted cash
issuance of 27,872 and 15,460 shares of common stock to fund the company’s 401(k) matching contribution for 2010 and 2009, respectively																																																					0	1,000	168,000
amortization and write-offs of patents																																																													95,000	5,000	281,000	34,000	110,000	68,000	171,000	136,000	326,000	297,000	142,000
third party royalty obligation																																																														1,000,000	500,000	300,000
proceeds from sale of common stock to genzyme																																																											0	0	6,000,000
payment for repurchase of stock options
issuance of 15,460 and 24,430 shares of common stock to fund the company’s 401(k) matching contribution for 2009 and 2008, respectively
issuance of 15,460 and 24,430 shares of common stock to fund the company’s 401(k) matching contribution for 2009 and 2008 respectively
issuance of 15,460 shares of common stock to fund the company’s 401(k) matching contribution for 2009																																																										65,000
restructuring																																																																								-281,718	0	0	282,000
warrant expense for license fees																																																											28,000
amortization of deferred revenue
increase in patent costs and other assets
payment to repurchase stock options
supplemental disclosure for non-cash investing and financing activities:
issuance of 24,430 shares of common stock to fund the company’s 401(k) matching contribution for 2008
issuance of 27,660 shares of common stock to fund the company’s 401(k) matching contribution for 2007																																																														1,000
depreciation and write-offs of fixed assets																																																														58,000			66,000	54,000	56,000
proceeds from sale of fixed assets
issuance of 34,030 shares of common stock to fund the company’s 401(k) matching contribution for 2006																																																																	0
issuance of 56,675 shares of restricted common stock to collaborator in lieu of cash to settle semi-annual license obligation																																																																	0	0	158,000
issuance of 56,675 shares of restricted common stock to collaborators in lieu of cash payments
issuance of 85,800 shares of common stock to fund the company’s 401(k) matching contribution for 2005																																																																				0
increase in restricted cash
non-cash revenue reduction recorded in connection with warrant extension																																																																								-629,370	0
net proceeds from sale of common stock																																																																												0	-78,000	43,383,000					-7,896
repayment of notes receivable																																																																											1,000	3,000	342,000	23,000	2,000	1,000	54,000
cash and cash equivalents, beginning of year
cash and cash equivalents, end of year
repurchase of restricted stock through forgiveness of notes receivable																																																																												2,000	0	83,000
forgiveness of notes receivable and accumulated interest																																																																												0	0	228,000
supplemental disclosure of non-cash financing activities:
deferred license fees
amortization																																																																									275,000	128,000	138,000	144,000	114,000	132,000	234,000	326,000	116,000
stock based compensation																																																																											303,000
adjustments to reconcile net income to net cash from operating activities –
non-cash stock-based compensation expense																																																																												154,000	120,000	126,000	329,000			567,801	865,887
amortization of deferred licensing fees
prepaid expenses
purchase of marketable securities
maturity and sale of marketable securities																																																																												15,686,000	5,768,000	9,168,000
adjustments to reconcile net income to net cash from operating activities
net sale (purchase) of marketable securities
purchase of treasury shares
sale of marketable securities																																																																																10,891,000	3,122,000
adjustments to reconcile net income to net cash from operating activities–
depreciation and amortization expense
amortization of licensing fees
non-cash expense associated with issuance of warrants
interest receivable
net proceeds from sale of preferred stock
proceeds from exercise of common stock options and purchase plans
repayment of stock subscription receivable																																																																																		189,410	3,940
sale of restricted stock through issuance of notes receivable																																																																																			-69
issuance of warrants to purchase common stock
purchase of treasury shares through the forgiveness of notes
equipment purchased through capital lease obligations
adjustments to reconcile net income to net cash from operating activities—
proceeds from exercise of common stock options and stock purchase plans																																																																																		65,987
repurchase of treasury shares
adjustments to reconcile net income to net cash from operating activities-
payments on capital lease bligations
net proceeds from sale of convertible preferred stock
adjustments to reconcile net income to net cash from operating activities;

We provide you with 20 years of cash flow statements for Exact Sciences stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Exact Sciences stock. Explore the full financial landscape of Exact Sciences stock with our expertly curated income statements.

The information provided in this report about Exact Sciences stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.